EULAR 2025 highlights… EULAR 2025 Highlights – Metabolic and Crystal arthropathies 18 Jul 2025 Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy: A phase 2, randomized, open-label, multi-center, active-controlled clinical trial Abstract format and assignment number: Oral presentation OP0299…
Metabolic & crystal arthropathies EULAR 2025: Do Not Miss – Metabolic & crystal arthropathies 1 Jun 20259 Jun 2025 Juan C Sarmiento-MonroyJuan C. is a Rheumatologist and clinical research fellow at the Hospital Clinic of Barcelona. His main research interests include the validation of biomarkers in RA-ILD and the…
EULAR 2024 Highlights… EULAR 2024 Highlights – Metabolic and Crystal arthropathies 21 Jul 202421 Jul 2024 Author: Juan C Sarmiento-Monroy Brikman et al. (OP0003) developed a machine learning-based prediction model for identifying hyperuricemic participants at risk of developing gout. The model demonstrated relatively good performance and…
Metabolic & crystal arthropathies EULAR 2024: Do Not Miss – Metabolic & crystal arthropathies 8 Jun 2024 Juan C Sarmiento-MonroyJuan C. is a Rheumatologist and clinical research fellow at the Hospital Clinic of Barcelona. His main research interests include the validation of biomarkers in RA-ILD and the…
ACR Highlights… ACR Convergence Highlights 2023 – Metabolic & Crystal arthropathies 9 Dec 20239 Dec 2023 Author: Dálifer Freites Núñez Tedeschi et al. (0234) performed a secondary analysis using data from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial. Among 6183 participants in this analysis,…
Metabolic & crystal arthropathies [EULAR HL 2023] Metabolic & crystal arthropathies 20 Jun 2023 Author: Juan C Sarmiento-Monroy Mccormick et al. (OP0258) evaluated the incident gout risk among metformin-treated patients with type 2 diabetes initiating SGLT2i vs. other second-line treatments in a population-based cohort study…